Journal of Cystic Fibrosis
Volume 6, Issue 2 , Pages 125-130 , April 2007

Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis—caution with trough concentrations

  • Kingsley P. Coulthard

      Affiliations

    • Adelaide Women's and Children's Hospital, Pharmacy Department, Australia
    • Corresponding Author InformationCorresponding author. Pharmacy Department, Adelaide Women's and Children's Hospital, King William Street, North Adelaide, 5006, South Australia, Australia. Tel.: +61 8 81616828; fax: +61 8 81616049.
    • ,
  • Daniel G. Peckham

      Affiliations

    • Regional Cystic Fibrosis Unit, Leeds, UK
    • ,
  • Steven P. Conway

      Affiliations

    • Regional Cystic Fibrosis Unit, Leeds, UK
    • ,
  • Carol A. Smith

      Affiliations

    • Pharmacy Department, Adelaide Women's and Children's Hospital, Cystic Fibrosis Clinic, Adelaide Women's and Children's Hospital, Australia
    • ,
  • Jan Bell

      Affiliations

    • Department of Clinical Microbiology, Adelaide Women's and Children's Hospital, Australia
    • ,
  • John Turnidge

      Affiliations

    • Adelaide Women's and Children's Hospital, University of South Australia, University of Adelaide, Australia

Received 14 October 2005 ,Revised 22 February 2006 ,Accepted 28 May 2006.

References 

  1. Master V, Roberts GW, Coulthard KP, et al. Efficacy of once-daily tobramycin monotherapy in acute pulmonary exacerbation of cystic fibrosis. Pediatr Pulmonol. 2001;31:367–376
  2. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J. 2002;19:303–309
  3. Smyth A, Tan K, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis—the TOPIC STUDY: a randomised controlled trial. Lancet. 2005;365:573–578
  4. Konrad F, Wagner R, Neumeister B, Rommel H, Georgieff M. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med. 1993;19:215–220
  5. Barclay ML, Begg EJ, Duffull SB, Buttimore RC. Experience of once-daily aminoglycoside dosing using a target area under the concentration–time curve. Aust N Z J Med. 1995;25:230–235
  6. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring. Simple or complex pharmacokinetic methods?. Clin Pharmacokinet. 2001;40:803–814
  7. Barclay ML, Kirkpatrick CMJ, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?. Clin Pharmacokinet. 1999;36:89–98
  8. Alvarez JS, Sacristan JA, Alsar MJ. Aminoglycosides: determination of new therapeutic ranges. Ann Pharmacother. 1991;25:558;[Letter to Editor]
  9. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39:15–20
  10. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605–609
  11. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988;158:831–847
  12. Tunridge J, Bell J, Mascaro L. The peak-AUC method for aminoglycoside dosage adjustment. In: Program and abstracts of 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. 1996 (September);Abstract
  13. Paterson DL, Robson JMB, Wagener MM, Peters M. Monitoring of serum aminoglycoside levels with once-daily dosing. Pathology. 1998;30:289–294
  14. Bates RD, Nahata MC, Jones JW, et al. Pharmacokinetics and safety of tobramycin after once-daily administration in patients with cystic fibrosis. Chest. 1997;112:1208–1213
  15. Vic P, Turck D, Husson MO, et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child. 1998;78:536–539
  16. Morris RG, Sallustio BC, Vinks AATMM, LeGatt DF, Verjee ZH, Desoky EE. Some international approaches to aminoglycoside monitoring in the extended dosing interval era. Ther Drug Monit. 1999;21:379–388
  17. Wallace AW, Jones M, Bertino JS. Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy. 2002;22:1077–1083
  18. Moore RD, Smith CR, Lipsky JD. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100:352–357
  19. Bertino JSJ, Brooker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of the significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167:173–179
  20. Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43:1549–1555
  21. Murry KR, McKinnon PG, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy. 1999;19:1252–1260
  22. Mann HJ, Canafax DM, Cipolle RJ, Daniels CE, Zaske DE, Warwick WJ. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr Pulmonol. 1985;1:238–243
  23. Jameson JP, Lewis JA. Three-point versus two-point method for early individualization of aminoglycoside doses. DICP Ann Pharmacother. 1991;25:635–637
  24. Lavezo LA, Davis RL. Two-versus three-sample method for estimating gentamicin pharmacokinetic values. Am J Hosp Pharm. 1994;51:1021–1024
  25. Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995;39:545–548
  26. Demczar DJ, Nafziger AN, Bertino JS. Pharmacokinetics of gentamicin at traditional versus high doses: Implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother. 1997;41:1115–1119
  27. Aminimanizani A, Beringer PM, King J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. JAC. 1992;50:553–559
  28. Smyth A, Touw D, Tan KHV, Bertenshaw C, Stableforth D. Tobramycin dosing in cystic fibrosis. Lancet. 2005;365:1767–1768[Letter to Editor]
  29. Kirkpatrick CMJ, Begg EJ. Aminoglycoside dosage regimens after therapeutic drug monitoring. Clin Pharmacokinet. 2002;41:791–792
  30. Mouton JW, Jacobs N, Tiddens H, Horrevorts AM. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis. 2005;52:123–127
  31. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114:194–198

☆ Presented at the Eighteenth Annual North American Cystic Fibrosis Conference, St. Louis, October 14–17, 2004.

PII: S1569-1993(06)00090-7

doi: 10.1016/j.jcf.2006.05.015

Journal of Cystic Fibrosis
Volume 6, Issue 2 , Pages 125-130 , April 2007

Article Tools